Key facts
- Elixirgen Therapeutics’s last known valuation is $67.0M (Nov 2023).
- It has raised $29.1M across 8 recorded rounds; the latest was Seed Round ($4.0M) in Oct 2025.
- Notable investors include The University of Tokyo Edge Capital, Sunovion Pharmaceuticals.
- Elixirgen Therapeutics has filed 9 Form Ds with the SEC since 2018, most recently Nov 2025 ($4.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Elixirgen Therapeutics
Funding rounds
8 roundsAbout Elixirgen Therapeutics
Developer of stem cell therapies designed for treating syndrome and Alzheimer's diseases through regenerative and rejuvenating medicines. The company's services focus on developing therapeutics from protein-based cells that utilize chromosomal features for increasing body immunity, screening DNA structures and eliminating drug-resistant bacteria and viruses, enabling medical researchers to get protein-cell-based therapies for curing chronic telomere diseases.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2012
- Employees
- 14
- Website
- elixirgentx.com/
- Ownership
- Privately Held (backing)
Elixirgen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elixirgen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elixirgen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.